Company intelligence / Profile preview
NanoMab Technology Limited
London, United Kingdomnano-mab.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
NanoMab has developed a pipeline of next-generation radiolabeled nanobody therapeutics and diagnostics targeting key oncology biomarkers. Lead asset NM‑01 has completed early clinical trials in China and entered Phase II trials in the UK for imaging PD-L1 expression in lung cancer. Other programs have reached early clinical stages or have been licensed to partners such as Radiopharm Theranostics and Full-Life Technologies for further development. The company’s approach enables both diagnostic imaging and targeted therapy using the same antibody scaffold labeled with different radioisotopes.
- Therapeutic areas
- Oncology
- Modalities
- Radiolabeled camelid single-domain antibodies (nanobodies)Diagnostic radiopharmaceuticalsTherapeutic radiopharmaceuticalsAntibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Lantheus Medical Imaging Inc.Radiopharm Theranostics (ASX:RAD)Full-Life Technologies HK Ltd.King’s College LondonUniversity Hospital Aachen
Beyond the preview
Go deeper on NanoMab Technology Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoMab Technology Limited.